Endocrine Abstracts

Background/objectives: This study aimed to investigate associations between self-reported sleep duration and general and abdominal obesity in Korean adults stratified according to sex and age.Subjects/methods: Data from 41,805 adults, 18–110 years of age, collected by the Korean National Health and Nutrition Examination Survey (KNHANES) in 2007 and 2015, were included. Obesity was defined as body mass index (BMI) ≥25 kg/m2, and abdo...

Object: The natural history and proper algorithm for follow-up testing of nonfunctioning pituitary adenomas (NFPAs) are not well known, despite their relatively high prevalence. The aim of this study was to suggest the optimal follow-up algorithm for NFPAs, based on the natural history.Methods: We followed up on 197 patients with NFPAs without any treatment (including surgery and radiation) at the time of detection, in a single center, between March 2000...

Introduction: Osilodrostat (oral 11β-hydroxylase inhibitor) demonstrated rapid, sustained cortisol normalisation in Phase III studies (LINC 3, NCT02180217; LINC 4, NCT02697734) in patients with Cushing’s disease (CD). Relative osilodrostat bioavailability is ~20% higher in Asian patients than other ethnicities; body weight is not a major determinant of this difference. This analysis of LINC 3 and LINC 4 evaluated osilodrostat efficacy and safety in Asian and non-Asia...

Introduction: Osilodrosat is a potent oral 11β-hydroxylase inhibitor. During the 24-week, single-arm, open-label period of the Phase III LINC 3 study (NCT02180217), osilodrostat treatment demonstrated rapid, sustained reduction in mean urinary free cortisol (mUFC) in most Cushing disease (CD) patients. In the subsequent 8-week, double-blind, randomized-withdrawal phase, a significantly higher proportion of patients receiving osilodrostat maintained normal mUFC at week (W)...

Introduction: In a Phase II study, osilodrostat, a potent oral 11β-hydroxylase inhibitor, normalized mean urinary free cortisol (mUFC) in most patients with CD. We report the efficacy and safety of osilodrostat in a large CD patient population (NCT02180217).Methods: In this study, open-label osilodrostat was initiated at 2 mg bid in 137 adults with CD and mUFC > 1.5 × ULN, with dose adjustments every 2 weeks (range 1–30 mg bid) up to ...